ΒιΆΉ΄«Γ½

Meeting Coverage

GuCS Future Focus

Future Focus from the Genitourinary Cancers Symposium

Second-Line Sacituzumab Govitecan Promising in Platinum-Ineligible UC

Further studies warranted in this sub-disease state, says Daniel Petrylak, MD

image

Latest GuCS Future Focus Meeting Coverage

Moving Newer Agents Up Earlier in Advanced Bladder Cancer

The future is "bright" with enfortumab vedotin and pembrolizumab, says Daniel Petrylak, MD

March 15, 2023
What if We Took an I-SPY2 Approach to Bladder Cancer?

Shilpa Gupta, MD, offered an interesting proposition at the Genitourinary Cancers Symposium

March 8, 2023
Emerging Therapies in Non-Muscle-Invasive Bladder Cancer

Gary Steinberg, MD, discusses key abstracts from the Genitourinary Cancers Symposium

March 1, 2023

Latest Oncology/Hematology Meeting Coverage